UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 10, 2015


 
WaferGen Bio-systems, Inc.
 
 
(Exact name of registrant as specified in its charter)
 

 
Nevada
 
000-53252
 
90-0416683
 
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 

 
7400 Paseo Padre Parkway, FremontCA
 
94555
 
 
(Address of principal executive offices)
 
(Zip Code)
 

(Registrant’s telephone number, including area code):  (510) 651-4450

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 







 
 

 

Item 5.07
Submission of Matters to a Vote of Security Holders

On June 10, 2015, WaferGen Bio-systems, Inc. (the “Company”) held its 2015 Annual Meeting of Stockholders. 4,751,513 shares of the Company’s common stock were present in person or by proxy at the meeting, representing approximately 83.95% of the 5,659,768 shares of common stock outstanding and eligible to vote. The certified results of the matters voted upon at the meeting, which are more fully described in the proxy statement for the Company’s 2015 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on May 11, 2015, which is incorporated by reference herein, are as follows:
 
 
  1.  The stockholders elected seven directors to the Board of Directors to serve for one year terms until the 2016 annual meeting of the stockholders or until their successors are duly elected and qualified, with the votes cast as follows:
 
 
Nominee
 
For
 
Withheld
 
Broker Non-Votes
 
Rolland Carlson
 
3,323,258
 
3,846
 
1,424,409
 
R. Dean Hautamaki
 
3,319,258
 
7,846
 
1,424,409
 
Makoto Kaneshiro
 
3,322,270
 
4,834
 
1,424,409
 
Joel Kanter
 
3,323,273
 
3,831
 
1,424,409
 
William McKenzie
 
3,320,253
 
6,851
 
1,424,409
 
Robert Schueren
 
3,323,220
 
3,884
 
1,424,409
 
Ivan Trifunovich
 
3,319,217
 
7,887
 
1,424,409
 
 
  2.
The stockholders ratified the appointment of SingerLewak LLP as the Company’s independent auditors for the fiscal year ending December 31, 2015, by the following vote:
 
 
For
 
Against
 
Abstain
   
 
4,739,196
 
111
 
12,206
   

 
  3.
The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, with votes cast as follows:
 
 
For
 
Against
 
Abstain
 
Broker Non-Votes
 
3,298,027
 
21,354
 
7,723
 
1,424,409




 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
WaferGen Bio-systems, Inc.
 
 
 
Date: June 10, 2015
By:
/s/ Michael P. Henighan
   
Name: Michael P. Henighan
   
Title: Chief Financial Officer